TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03112174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibrutinib
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Administered orally once daily
Study: NCT01400022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UVA1 phototherapy
Description: The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone
Description: Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
Study: NCT01294098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: 0.75 cc/kg of 1/4% Marcaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: 0.75 cc/kg of 1/4% Marcaine
Study: NCT02414529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: Ergocalciferol 5000 units capsules given. 300,000 units PO once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02121665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic (Inersan)
Description: Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Study: NCT03101553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification
Description: Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to negative evaluation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Eight 15-minute sessions of progressive muscle relaxation (PMR).
Study: NCT03112174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral tablet to match Venetoclax
Description: Administered orally once daily
Study: NCT04567186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational senofilcon A C3 Multifocal Lens
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational senofilcon A C3 Multifocal Lens
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A Multifocal Lens
Description: Dailies Total 1® Multifocal Contact Lens
Study: NCT01592760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q SP
Description: air-Q SP placement for airway maintenance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: air-Q
Description: air-Q placement for airway maintenance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel
Description: i-gel placement for airway maintenance.
Study: NCT01428401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb Astragalus membranaceus
Description: Astragalus membranaceus ( AM) at a rate of 3 g three times per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: at a rate of 3 g three times per day
Study: NCT01637142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-LY2140023
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-LY404039
Description: Administered IV.
Study: NCT01471080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: using RFA to treat cavernous hemangiomas

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatectomy
Description: using hepatectomy to treat cavernous hemangiomas
Study: NCT01989000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadobutrol
Description: 0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadobutrol
Description: 0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [F-18]HX4
Description: 400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [F-18]HX4
Description: 400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
Study: NCT04567186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A Multifocal Lens
Description: Dailies Total 1® Multifocal Contact Lens
Study: NCT01908725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: ERT, i.v. infusions weekly
Study: NCT01989000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2/dose on day 1 and 8 in 2 cycles of 21 days (three weeks) each, one cycle before and one cycle after radiochemotherapy. During radiotherapy gemcitabine is administered at 1000 mg/m2/dose on day 1, 8 and 15.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: A hypofractionated scheme of 15 fractions of 2.4 Gy in three weeks will be applied, combined with the second course of gemcitabine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Study: NCT03959878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constant Pressure Skin Disk
Description: The external disk is made of Dow Corning® Silastic Q7-4850 liquid silicone rubber. Placement of the disk will be done by the gastroenterologist or interventional radiologist during the gastrointestinal gastrostomy tube (GIG) or gastrointestinal jejunostomy tube (GIJ) placement procedure. The gastroenterologist or interventional radiologist will replace the manufacturer's external, adjustable skin disk with the external, adjustable Constant Pressure Skin Disk, by sliding the former off and the latter on to the feeding tube.
Study: NCT04203030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will meet in a weekly group session to discuss a topic related to physical activity and physical function and participate in group-based physical activity. Participants will also have instructions to participate in physical activity outside of the weekly sessions, incrementally increasing their total physical activity over the intervention period.
Study: NCT05019469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhythmic vibration cueing (lower leg)
Description: A non-invasive wearable device worn against both gastrocnemius muscles provides rhythmic vibrations when triggered.
Study: NCT01126736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (eribulin; E7389)
Description: Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
Study: NCT01371162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5428029
Description: Multiple ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5428029
Description: Multiple ascending doses
Study: NCT01072344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chamomile (Matricaria recutita)
Description: 500 mg 3 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chamomile (Matricaria recutita)
Description: 500 mg 3 times daily
Study: NCT04285385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Description: 0.10 ml of lavender essential oil

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham aromatherapy
Description: 0.10 ml of mineral oil
Study: NCT00599807

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (cholecalciferol)
Description: the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (cholecalciferol)
Description: the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
Study: NCT02160405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: native potato
Study: NCT01567098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single incision laparoscopic appendectomy
Description: performing appendectomy through a single incision in the abdomen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single incision laparoscopic appendectomy
Description: performing appendectomy through a single incision in the abdomen
Study: NCT02668146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Study drug will be administered to study subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to study subjects
Study: NCT05911100

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirography and assessment of pulmonary diffusion capacity
Description: Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary stress test
Description: The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography of the chest organs
Description: CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department.

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart echocardiography
Description: It's a specific method of ultrasound examination, which consists in examining the heart in real time and usually does not cause any unpleasant feelings

Intervention type: OTHER
Intervention: SF-36 Quality of Life Questionnaire
Description: https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf

Intervention type: DIAGNOSTIC_TEST
Intervention: Demographic and antropometric measures
Description: Age, sex, height. weight, body mass index (BMI)

Intervention type: OTHER
Intervention: Indicators characterizing the severity of the underlying disease
Description: * Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease)~* Medications taken.
Study: NCT02605642

Intervention type: DRUG
Intervention: CT-P13
Description: biosimilar infliximab
Study: NCT01745640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POMALIDOMIDE
Description: hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg (if patient \<75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
Study: NCT02584491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional gait-related training
Description: The motor learning (ML)-based functional gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Scheduling flexibility will promote adherence, with a minimum one day between sessions to provide opportunity for rest. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined active/imagery) will be five per week.
Study: NCT00235131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Stent
Description: Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Luminexx Stent
Description: Bard® Luminexx™ 6F Vascular Stent
Study: NCT01371162

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple doses
Study: NCT00746967

Intervention type: DRUG
Group type: OTHER
Intervention: sildenafil
Description: sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
Study: NCT02111564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 10 mg
Description: Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (\>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 7.5 mg
Description: Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from \>=30 to less than (\<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
Study: NCT02592889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MITRACLIP
Description: MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM
Study: NCT03459027

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Super Beets
Description: Nitrate rich beetroot powder (10g) acutely

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Super Beets
Description: Nitrate rich beetroot powder (10g) acutely

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot powder
Description: Nitrate devoid beetroot powder (10g) acutely

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot powder
Description: Nitrate devoid beetroot powder (10g) acutely
Study: NCT03018886

Intervention type: OTHER
Group type: OTHER
Intervention: GHRH plus arginine test
Description: One ug/kg GHRH \[GHRH(1-29), GEREF Serono, Italy\] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GHRH plus arginine test
Description: One ug/kg GHRH \[GHRH(1-29), GEREF Serono, Italy\] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
Study: NCT02488304

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HRCT scans
Description: A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7.~An upper airway (UA) scan will be taken on visit 2.
Study: NCT02761083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novosyn® Quick
Description: Eye surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl® Rapid
Description: Eye surgery
Study: NCT02135731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review software with pictures
Description: The intervention is a self-service software program that displays each prescription on screen along with an image of the pharmaceutical product. Patients must use response buttons to describe adherence patterns and to advance through the questionnaire items.
Study: NCT00391404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70 mg weekly (oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00388050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Medication Choice decision aid
Description: The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
Study: NCT01286961

Intervention type: DRUG
Intervention: bowel preparation using split dose of polyethylene glycol
Description: polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
Study: NCT00605956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NatrOVA Creme Rinse - 1%
Description: NatrOVA Creme Rinse - 1% spinosad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NatrOVA Creme Rinse Vehicle Only
Description: NatrOVA Creme Rinse Vehicle - no spinosad

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Blank Patch
Description: Blank Patch
Study: NCT00095147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Description: Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab (INF) + MTX, DB
Description: Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
Study: NCT00388050

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
Study: NCT00095147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLA) + MTX, DB
Description: Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLA + MTX switched to ABA+ MTX, DB
Description: Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABA, open-label (OL)
Description: Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
Study: NCT00470509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 2 subcutaneous injections on day 0 and 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 2 subcutaneous injections on day 0 and 7
Study: NCT00865384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REMERON® 15 mg tablets, single dose
Description: B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
Study: NCT00319969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Study: NCT01812447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiration Valve System
Description: Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiration Valve System
Description: Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
Study: NCT00319969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 1.5mg/m\<2\> IV days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.